A collaborative effort is underway to advance the development of a novel class of therapeutics targeting disease-causing proteins. Leading European research institutions, including those in Frankfurt, Barcelona, Dundee, Lausanne and Vienna, have announced the formation of a European Alliance for Proximity-Inducing Compounds.
This innovative approach focuses on selectively removing proteins implicated in various diseases, opening potential treatment avenues for targets previously considered untreatable. The alliance aims to consolidate expertise, infrastructure and digital platforms, streamlining access to crucial technologies and resources.
Researchers involved emphasize the potential for these strategies to redefine drug development paradigms. By linking national initiatives with leading international institutions, the collaboration anticipates accelerating the pace of innovation in the field.
The participating centers bring together complementary strengths in areas such as medicinal chemistry, structural biology and computational methods. Authors of the announcement highlight the fundamental role of academic research and call for increased collaboration between the scientific community and industry partners to fully unlock the therapeutic possibilities of proximity-inducing compounds.
